When following their analytic and scoring guidelines, the IKWG concluded that Ki67 IHC cut points of ≤ 5% and ≥ 30% have sufficient clinical utility for patients with ER+HER2− stage I/II breast cancer and can be used to identify patients who can avoid or proceed with chemotherapy. Here, ERBB2 is linked to breast cancer.